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Abstract The tetracycline-controlled transcription system has
become one of the most potent systems for experimental
manipulations of transcription levels in vivo. Here we report on
rtTA variants, which were generated by combining the existing
positively regulated Tet repressor domains of rtTA and rtTA-M2
with a modified and multimerized minimal transactivation
domain from VP16 (L-domain). A transactivator with multi-
merized L-domains shows drastically reduced background
activity and enhanced transcriptional activation on different
tetracycline-responsive promoters. The new rtTA variants
require higher doses of doxycycline and display a more linear
dose^response curve than the original rtTA or rtTA-M2
proteins. ß 2002 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The tetracycline-controlled transcription system (Tet-system
[1]) consists of a tetracycline- or doxycycline-dependent trans-
activator protein and an arti¢cial promoter activated by this
transactivator. The transactivator is a fusion protein of the
Tet repressor (TetR) of Escherichia coli (Tn10) and part of the
transcriptional activation domain of Herpes simplex protein
16 (VP16). The target promoter of this transactivator com-
prises an array of tetO-sequences from the Tn10 operon and a
minimal core promoter derived from the cytomegalovirus im-
mediate early promoter (CMV). Two types of transactivators
have been developed. The tTA (tetracycline-controlled trans-
activator) binds and activates the operator/responder con-
struct in the absence of tetracycline [1]. Mutants thereof con-
taining amino acid substitutions in the TetR moiety exhibit a
reverse phenotype [2,3], i.e. can only activate transcription in
the presence of certain tetracycline derivatives. These mutants,
called rtTA (‘reverse tetracycline-controlled transactivator’)
and rtTA-M2, require doxycycline or anhydrotetracycline
for optimal function. Although both the negatively controlled
system and the positively controlled rtTA have been used to
study gene function in various organisms [4,5^9], particularly
the original rtTA [2] shows some limitations. Among these are
a high background activity in the non-induced state due to a
residual a⁄nity to tetO and a higher instability in some cell
lines and tissues when compared to tTA [3]. Several attempts
have been made to improve and modify the Tet system [3,10].
Some derivatives of tTAs exhibited improved properties in
activation, doxycycline sensitivity, and stability [3]. By using
a multimer of four VP16-derived minimal activation domains
[12,13] a new transactivator protein (unchanged in the TetR
sequence) was generated whose activation power exceeded
that of the original tTA by a factor of 2.3 [10]. This approach
has only been described in detail for the tTA system. Since in
many biological systems the application of a positively con-
trolled transactivator is desirable (faster onset, easier and
cheaper handling for short time induction, especially in trans-
genic animals), we tried to modify and enhance this kind of
transactivator protein. Here we describe such improved rtTAs
containing multimers of a mutated minimal activation do-
main. Usage of the earlier described minimal activation do-
main (‘F-domains’), which has been e¡ective for the tTA [10],
showed no e¡ect when fused to the rtTA and no improvement
was seen for the rtTA-M2. Substantial enhancement was seen
using mutated domains lacking the phenylalanine at position
442, even though this residue was previously shown to be
essential for activity [12,13].
2. Materials and methods
2.1. Synthesis of minimal activation domains
The minimal activation domains (‘F-domain’) were used as de-
scribed previously [10]. Domains were synthesized by PCR using the
‘Tet-On’ plasmid (Clontech) as a template. For simplicity we follow
the Clontech nomenclature with pUHD17-1neo [2], named Tet-On,
indicating the rtTA protein including the complete VP16-domain.
Following primers were used: Ffw 5P-TAT ACG CGT TGC ATG
CCG ACG CG-3P ; Frv 5P-ATG CGC GCC CAA CAT GTC CAG
A-3P. The primers introduced an MluI restriction site at the 5P-end
and a BssHII site at the 3P-end, allowing ligation of the resulting
fragment into BssHII-digested plasmids pTet-On and prtTA-M2 (for
simplicity named M2). BssHII digestion eliminates the VP16-domain
in frame. The two enzymes generate compatible cohesive ends. Only
with F-domains inserted in the correct orientation was the construct
recleavable with BssHII at the 3P-end. The stop codon and poly A
signal were then reintroduced via a PCR-product with MluI- and
PvuII-ends generated on pTet-On. L-domains arose as a PCR artefact
and were multimerized and cloned as described.
2.2. Transient transfections
Transfections of NIH/3T3 cells were performed at 60^70% con£u-
ence using Rotifect (Carl Roth, Karlsruhe, Germany, 3.0 Wl/Wg DNA)
or Superfect (Qiagen, Hilden, Germany, 5 Wl/Wg DNA) in 12 well
dishes according to the instructions of the distributor. The DNA
mixtures contained 0.25 Wg of transactivator constructs and in the
case of transient/transient transfections 0.25 Wg of the Luciferase en-
coding responder construct pTRE-Luc (Clontech, La Jolla, USA),
originally described as pUHC-13-3 [1]. For normalization of trans-
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fection e⁄ciency, 0.015 Wg of a pCMV-L-galactosidase plasmid was
cotransfected to each well. Doxycycline (Sigma) was added at concen-
trations of 0^5 Wg/ml. Cells were harvested 24 h after induction for
luciferase assays.
2.3. Luciferase and L-galactosidase assays
Cells were washed once with 2 ml PBS/well and cell lysates were
prepared by adding 100 Wl of 100 mM potassium phosphate lysis
bu¡er (pH 7.8, 1 mM DTT, 0.2% Triton X-100). 10^50 Wl were
used to perform luciferase assays as described [14]. Protein content
of the lysates was determined according to Bradford [15]. Luciferase
activity was measured using an Autolumat LB953 (Berthold, Wild-
bad, Germany) using the integral mode (20 s) after a delay time of
20 s. L-Galactosidase activity was determined using the ‘Galacto-light’
kit (Tropix, Bedford, MA, USA) according to the suppliers instruc-
tions with measurement performed in the Autolumat LB953 (signal
integration over 20 s).
2.4. Western blot analysis
NIH/3T3 cells were grown in 92 mm dishes to 70% con£uence and
transfected transiently with 10 Wg of plasmid DNA encoding the dif-
ferent transactivator fusion proteins. After 24 h nuclear extracts of the
cells were collected as described in [16]. 50 Wg of nuclear protein were
separated on SDS^PAGE (10% acrylamide:bis-acrylamide, 29:1) and
electroblotted onto Hybond C (Amersham Pharmacia Biotech,Piscat-
away, NY, USA) blocked in a solution of 10% (v/v) fetal calf serum
(Biochrom, Berlin, Germany) in Tris-bu¡ered saline (TBS; 50 mM
Tris/150 mM NaCl). For immunochemical detection of the rtTA var-
iants a monoclonal ‘TetR’ antibody (MoBiTec, Go«ttingen, Germany)
was used in TBS containing 2% fetal calf serum.
2.5. Electrophoretic mobility shift assay
NIH/3T3 cells were transfected and nuclear proteins were prepared
as described in [16]. The tetO fragment was generated by annealing of
two oligonucleotides resulting in a double-stranded tetO fragment
with unpaired guanine residues at the 5P-ends of the primers. The
protruding ends were labelled with [KP-32P]dCTP. Aliquots of the
protein extracts (10 of 150 Wl) were used as described in [17].
2.6. Stable cell lines
NIH/3T3 cells were grown in 92 mm dishes to a con£uence of
30^40% and transfected with 10 Wg DNA. The transfection assay
contained the responder plasmid pTRE-Luc (see Section 2.2) and
pTK-Hyg (Clontech) to establish a hygromycin resistance, in a molar
ratio of 3:1. Transfection was done as described before. 24 h after
transfection the cells were plated to less than 10% con£uence. After
further 24 h the selection was started by addition of 100 Wg hygro-
mycin/ml. Resistant clones were isolated, expanded separately, and
analyzed for doxycycline-inducible luciferase activity after transient
transfection of the rtTA-encoding plasmid pTet-On.
3. Results
3.1. Fusions between rTetR and minimal activation domains
derived from VP16
A minimal activation domain (F) encoding the acidic tran-
scriptional activation domain of VP16 (positions 436^447)
was synthesized following the approach of Baron et al. [10]
to modify the tTA protein. Two to eight copies were fused to
the 3P-end of the rTetR or rTetR-M2 domain in frame (Fig. 1).
The second type of minimal activation domain (named ‘L’, for
‘lacking’) lacked the amino acid positions 442 and 443 (phe-
nylalanine and aspartate) of the original VP16-derived F-do-
main. One to 20 copies of the L-domain were inserted into
pTet-On and pM2 (Fig. 1). Constructs were named according
to the number and type (F or L) of minimal activation do-
main copies. The identity of each construct was con¢rmed by
dideoxysequencing and restriction digestion (Fig. 2A).
3.2. Characterization of Tet-On-derived constructs
For characterization of new Tet-On-derived rtTA variants
we performed Western blot analysis of nuclear extracts of
transiently transfected NIH/3T3 ¢broblasts (Fig. 2B). In every
lane a distinct product can be seen, while the sizes increase
according to the number of L-domains. The doxycycline-de-
pendent binding of the rTetR fusion proteins was examined
by electrophoretic mobility shift assays. Nuclear protein ex-
tracts were incubated with radioactive labelled tetO DNA
(Fig. 2C). Retarded complexes can be seen in lanes with nu-
clear protein plus doxycycline. Weaker signals appear without
doxycycline with each of the three tested transactivators (Tet-
On, 10L, 16L) re£ecting residual promoter-binding activity
without inducer. The di¡erence between the induced and
Table 1
Transcriptional activation of TRE-Luc responder by di¡erent Tet-On-derived transactivators in double transient transfections
RLUs (%) 3 doxycycline RLUs (%) + doxycycline Relative activationa
Tet-On 10.2( þ 2.7) 100 10.4( þ 2.5)
8L 2.4( þ 0.8) 44.5( þ 10.4) 19.5( þ 5.6)
10L 3.0( þ 2.5) 55.6( þ 27.8) 24.6( þ 7.5)
16L 2.4( þ 2.4) 90.2( þ 71.5) 40.4( þ 7.8)
17L 2.8( þ 1.9) 118.7( þ 82.5) 43.1( þ 6.9)
20L 4.4( þ 3.7) 133.8( þ 72.1) 34.2( þ 6.9)
4F 14.2( þ 6.8) 68.0( þ 22.6) 4.9( þ 1.5)
6F 11.4( þ 2.3) 43.2( þ 14.7) 3.0( þ 0.6)
8F 11.6( þ 4.9) 29.4( þ 17.0) 2.5( þ 0.5)
Relative activation factors were measured in double transient transfection assays with the respective transactivators and TRE-Luc with or with-
out doxycycline. Tet-On plus TRE-Luc plus doxycycline was set as 100%.
aThe average relative activation factor is calculated from values of the single transfection assay and is therefore not calculable from the average
RLUs of this table.
Fig. 1. Replacement of the VP16 activation domain of Tet-On and
M2 with minimal activation domains. Scheme of the addition of
minimal activation domains to rTetR or rTetR-M2. F denotes the
minimal activation domain used by Baron et al. [10], corresponding
to the VP16 wild-type sequence positions 436^447. The modi¢ed
L-domain lacks positions 442 and 443 (phenylalanine and aspar-
tate). Two amino acids at the N-terminus boxed are added due to
the cloning strategy.
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uninduced state appeared most pronounced in the case of the
16L transactivator.
3.3. Activation potential of minimal activation domains
To assess the activation potential of the modi¢ed transacti-
vator proteins, NIH/3T3 cells were transfected with the Tet-
responsive luciferase reporter plasmid pTRE-Luc together
with the respective activator constructs (transient/transient).
Luciferase activity was ¢rst calculated as relative light units
(RLUs)/Wg protein and then normalized for transfection e⁄-
ciency by L-galactosidase activities resulting from uninduced
wells. This was necessary because the L-galactosidase activities
in the doxycycline-induced wells were reduced to 1/2^1/3 of
the uninduced wells. Calculating with reduced L-galactosidase
activities would have inadmissibly changed the activation fac-
tors. In initial experiments, pools of suspended cells were
transfected and split into four (duplicates with and without
doxycycline), ensuring identical transfection e⁄ciency for all
wells. Since experiments on plated cells showed identical re-
sults, we continued to transfect adherent cells because of high-
er transfection e⁄ciency. Luciferase activity obtained in tran-
sient/transient transfections with pTRE-Luc plus pTet-On or
pM2 was set as 100%. All other values obtained with the
corresponding transactivator variants (uninduced or induced)
were related to this activity. Values in Tables 1^3 are mean
values from 6^10 transfections.
The F-domain fusions, which were previously reported to
be e¡ective in combination with the Tet and the rTet-M2 re-
pressor part [10,3], showed no increased activation potential
after addition of doxycycline when compared to the originally
described rTetR-VP16 and rTetR-M2-VP16 fusion proteins
(pTet-On, prtTA-M2)(Table 1). In addition, the uninduced
background of luciferase activity increased upon inclusion of
further minimal domains of the F-type. Transactivators with
multimers of L-type domains showed no or minimal activa-
tion potential when four, ¢ve, or six minimal domains were
used. A signi¢cant improvement was observed with fusions of
more than eight L-domains. We observed an increase of the
activation potential of Tet-On-derived constructs up to 17
multimerized L-domains, due both to an increase in absolute
activity and to a reduced background (Table 1).
Combining the new rTetR-M2 repressor with F-domain
multimers reduced activation potentials to about 20% of
that seen with the unmodi¢ed M2 (not shown). With multi-
mers of L-domains we observed a similar but less strong en-
hancement as described above for the Tet-On variants (Table
2). However, in contrast to the Tet-On derivatives, the highest
increase in activation potential was reached with 11 multimer-
ized L-domains but did not exceed the activation potential of
M2 when the reporter TRE-Luc was used. Adding further
L-domains led to an increased absolute activity without
changing the activation capacity, because background activity
also increased.
3.4. Characterization of the activation potential of L-domain
rtTAs in cell lines containing stably integrated responder
constructs
To model a more de¢ned experimental setting, i.e. to pro-
vide a de¢ned responder condition and to reduce the lucifer-
ase background seen in transient/transient transfections, we
used NIH/3T3 cell lines stably transformed with the responder
construct pTRE-Luc as host for transient transfection of the
Fig. 2. Characterization of Tet-On (containing the VP16-domain)
and Tet-On-derived L-transactivator constructs. A: Separation of
HindIII-digested DNA of the constructs showing the steps of multi-
merization with pTet-On on the left site and the corresponding
rTetR fusion constructs with increasing numbers of minimal activa-
tion domains (L-type). B: Western blot analysis of Tet-On and
L-domain constructs. NIH/3T3 cells were transiently transfected
with the respective constructs and nuclear extracts were subjected to
Western analysis with anti-TetR antibody. C: Characterization of
the DNA-binding properties of some rTetR fusions with electropho-
retic mobility shift assays. Nuclear cell extracts were prepared from
transiently transfected NIH/3T3 cells 24 h after transfection. Ex-
tracts (50 Wg nuclear protein) were incubated with radioactive la-
belled tetO DNA in presence or absence of doxycycline, and com-
plexes were separated electrophoretically.
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rtTA constructs. Di¡erent stable clones were transfected with
plasmids encoding the original transactivator (Tet-On, i.e.
rTetR-VP16) or with DNA encoding some of the L-domain
variants. Three TRE-Luc-containing clones, numbers 21, 29,
and 30, were chosen to show di¡erences in induction proper-
ties of luciferase activity caused by di¡erences in copy number
and chromosomal integration site. In every case the activation
factor of luciferase activity was higher in these transient/stable
transfection assays than in transient/transient transfections
(Tables 1 and 3). L-domain transactivators gave higher acti-
vation factors than did Tet-On (Table 3). The increase in
activation was speci¢c for each of the responder clones. The
best performing constructs (rTetR-16L, rTetR-17L) gave a ca.
10-fold larger activation factor compared to Tet-On in clones
21 and 30, and ca. 2.5-fold higher in clone 29. This increase in
activation factor was caused in part by higher induced activity
in clones 21 and 30 (2.8^4.3-fold more than given by Tet-On),
and by lower uninduced background activity in all three
clones.
3.5. rtTA-dependent transactivation from plant-derived tetO
promoter constructs
To further explore the capability of our new transactiva-
tors, we used two newly developed tetO-containing promoter
constructs (Tax-Luc and TopFree-Luc) based on plant virus
CaMV minimal promoter sequences [18,19](Table 2). As in
the previous experiments, activity of the original Tet-On or
M2 (RLU/Wg protein normalized by L-galactosidase activity)
with the respective responder was set as 100% and all other
activities were related to this value. Background activity
(which combines basal activity of the promoter alone plus
residual activity of the transactivator without doxycycline) is
lower for the plant-derived promoters than for the TRE-Luc
responder with any of the transactivators, and is almost non-
existent with the L-domain transactivators. This results in
very high relative activation factors of 300^600 (in transient/
transient transfections). However, the absolute activity which
can be achieved in NIH/3T3 cells transiently cotransfected
with Tet-On-17L and either Tax-Luc or TopFree-Luc is
only about 70^90% of than seen with Tet-On activity. In
case of the modi¢ed M2 we reach 50^60% of M2 activity
with the M2-11L. In general the L-variants gave much higher
activation factors than did the VP16-containing transactiva-
tors (Tet-On and M2) when they were combined with the
plant-derived tetO promoter constructs.
3.6. Response of di¡erent transactivators to varying
concentrations of doxycycline
To compare the response of the original transactivators and
the L-variants to varying doxycycline concentrations, we
transfected the best inducible responder-containing clone
(number 30, Table 3) with the respective activator construct
and measured luciferase activity after incubation with di¡er-
ent concentrations of doxycycline (Fig. 3). Activation of the
original Tet-On occurred in a very narrow concentration win-
dow, with maximum induction reached at 0.5 Wg doxycycline/
ml. The dose^response curve for the 17L was much less steep,
and almost linear from 0.1 to 1 Wg doxycycline/ml, with ca.
2 Wg/ml being required for full activation. Full activation of
the M2 and M2-11L was obtained using approximately 0.2 Wg/
ml and 1 Wg/ml doxycycline, respectively, with the curve for
the L-derivative again being less steep.
4. Discussion
The primary goal of this study was to improve the activation
potential of the positive tetracycline (doxycycline) -dependent
transactivator (rtTA) [2]. Similar to the approach described by
Baron et al. [10] for modi¢cation of the tTA we fused the same
minimal activation domain derived from VP16 to the rtTA
and the rtTA-M2 DNA-binding domain. Gene synthesis
PCR reactions produced both the actual F-domains and a
mutant thereof (presumably as a PCR artefact), which we
called the L-domain. This mutant lacked two amino acids
(positions 442 and 443), including Phe442, which had been
reported to be of crucial importance for function of the
VP16 transcription activation domain [12,13]. Multimers of
the minimal activation domains (F-domains), which were de-
scribed to be functional when fused to the TetR [10], showed
no e¡ect when fused to reversed TetR. In fact, the background
Table 2
Transcription activation in NIH/3T3 cells transiently transfected with di¡erent activator and responder constructs
Transactivator RLUs (%) 3 doxycycline RLUs (%) + doxycycline Activation factora
TRE-Luc
Tet-On 10.2( þ 2.7) 100 10.4( þ 2.5)
16L 2.4( þ 2.4) 90.2( þ 71.5) 40.4( þ 7.8)
17L 2.8( þ 1.9) 118.7( þ 82.5) 43.1( þ 6.9)
M2 1.2( þ 0.5) 100 89.8( þ 38.6)
M2-11L 0.6( þ 0.04) 42.8( þ 13.4) 72.1( þ 23.9)
M2-16L 1.0( þ 0.5) 58.9( þ 15.9) 70.3( þ 11.5)
Tax-Luc
Tet-On 3.01( þ 2.1) 100 56.6( þ 31.3)
16L 0.17( þ 0.1) 84.8( þ 29.9) 401.9( þ 156.6)
17L 0.26( þ 0.1) 100.4( þ 63.1) 508.0( þ 385.3)
M2 0.4( þ 0.1) 100 221.8( þ 43.5)
M2-11L 0.06( þ 0.02) 36.3( þ 10.8) 541.3( þ 109.2)
TopFree-Luc
Tet-On 2.66( þ 1.57) 100 54.6( þ 18.5)
16L 0.33( þ 0.15) 69.5( þ 7.1) 333.2( þ 72.6)
17L 0.27( þ 0.15) 67.8( þ 25.7) 338.2( þ 154.3)
M2 0.5( þ 0.2) 100 191.8( þ 59.8)
M2-11L 0.08( þ 0.02) 53.0( þ 10.8) 642.8( þ 198.3)
M2-16L 0.1( þ 0.04) 82.3( þ 20.6) 553.6( þ 166.4)
aThe average relative activation factor is calculated from values of the single transfection assay and is therefore not calculable from the average
RLUs of this table.
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activity (non-induced state) increased with increasing numbers
of F-domains. Urlinger et al. reported a similar observation
[3]. In contrast to this, multimers of the mutant minimal acti-
vation domain (L-domains) displayed a steady increase of
doxycycline-dependent transcription activation (Table 1).
This is mainly due to a strongly reduced background expres-
sion from the tetO7 promoter in the uninduced state. With
more L-domains we observed a slight increase of background
activity, but the absolute response upon induction was still
higher than with Tet-On, resulting in an optimum of tran-
scriptional activation at 16^17 L-domains (Table 1). Tet-On/
L-domain constructs exhibited superior activation properties
both in transient/transient and in transient/stable assays with
di¡erent Tet-responsive promoters (Tables 2 and 3).
When we fused L-domains with rTetR-M2 [3], an improved
reversed TetR version, we found an optimal of transcriptional
activation with 10^12 L-domains and an increase in back-
ground with higher numbers of L-domains. At least with
TRE-Luc as responder this activation is slightly below that
of the VP16-containing M2. We did not see any signi¢cant
activation potential with M2/F-domain constructs. Urlinger et
al. [3] described a 3F-domain to be an equally e¡ective trans-
activator domain as VP16. However, this was in the context
of rTetRS-M2, a codon usage optimized version. Our experi-
ments were performed with the non-humanized M2 version to
allow a comparison with the original rtTA version.
L-Galactosidase activities from induced cells (plus doxycy-
cline) were reduced to about 50% of the activity from unin-
duced samples. This may be a squelching e¡ect arising from
depletion of general transcription factors through non-speci¢c
formation of transcription complexes by the VP16-domain
(independently from tet-promoter sequences and doxycycline).
Squelching has been described for GAL4 [11] and VP16 do-
mains, and has been suggested for tTA because this trans-
activator is only tolerated in limited amounts by cells [4].
Since the rtTA protein has been described as inherently insta-
ble [3] and L-galactosidase repression occurs when doxycycline
is added, we speculate that doxycycline might stabilize this
transactivator and thus potentiate the squelching e¡ect.
Electrophoretic mobility shift assays with Tet-On/L-domain
constructs (Fig. 2C) demonstrated a reduced background af-
¢nity (without doxycycline) of L-domains for the tetO7 se-
quence element. Note that in Fig. 2B,C similar amounts of
cellular protein and (according to the Western blot) compa-
rable amounts of reverse transactivator resulted in clearly re-
duced signals in the band shift experiment with 10L. Accord-
ing to our results Phe442 seems not to be essential for
transactivation activity of the VP16 minimal domain. Since
even the absolute reporter activity with 8F is lower than
with 8L (Table 1) it seems that in our system the loss of the
Phe442 residue in fact is bene¢cial for the activation power of
the whole complex.
Highest induction rates could be achieved by using novel
Tet-responsive promoters designed by Bo«hner et al. [18,19].
As shown in Table 3, the 16L transactivator again is superior
to the original Tet-On, giving activation with almost no back-
ground even in transient transfection. However, absolute
strength of reporter activity is diminished in this combination.
Thus, in our hands highest activation factors with the variants
of Tet-On were obtained with the combination of 16L/Tax-
Luc and highest absolute RLU values were obtained with
20L/TRE-Luc.
In case of the rTetR-M2, an L-domain-based improvement
of the activation potential was only observed when the com-
pared transactivators M2 (rTetR-M2-VP16) or M2-11L
(rTetR-M2-11L) were cotransfected with the responder con-
structs Tax-Luc or TopFree-Luc. This improvement was
weaker than that seen for the rTetR variants (i.e. Tet-On
versus 17L). However, this result ¢ts well with the observation
that L-domains were able to improve the activation potential
Table 3
Transcription activation in stably transformed NIH/3T3 responder cell lines by transient transfection of di¡erent Tet-On derived activator con-
structs
Transactivator Responder (TRE-Luc, stable) RLUs (%) 3 doxycycline RLUs (%) + doxycycline Activation factora
Tet-On clone 21 2.1( þ 0,8) 100 54.8( þ 19.6)
16L clone 21 0.5( þ 0.4) 282.2( þ 77.3) 639.2( þ 287.6)
Tet-On clone 29 2.1( þ 0.8) 100 42.4( þ 12.6)
16L clone 29 0.8( þ 0.3) 80.0( þ 24.1) 106.0( þ 54.5)
Tet-On clone 30 3.2( þ 0.9) 100 33.3( þ 7.5)
10L clone 30 1.0( þ 0.5) 118.0( þ 22.1) 148.3( þ 94.0)
16L clone 30 1.6( þ 0.8) 430.7( þ 215.4) 287.3( þ 63.6)
17L clone 30 1.6( þ 1.0) 380.6( þ 151.7) 256.2( þ 60.3)
Activation factors were measured by transient transfection of indicated transactivators in di¡erent stable responder clones. Tet-On plus TRE-
Luc plus doxycycline was set as 100% and is speci¢c for each responder line.
aThe average relative activation factor is calculated from values of the single transfection assay and is therefore not calculable from the average
RLUs of this table.
Fig. 3. Doxycycline requirement of Tet-On, 17L, M2 and M2-11L.
The stable responder clone TRE-Luc 30 (see Table 3) was transi-
ently transfected with a single transactivator construct and was cul-
tivated with di¡erent concentrations of doxycycline. Luciferase ac-
tivity was measured 24 h after transfection. 5 Wg doxycycline/ml
medium was set as 100% activation.
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of the rTetR-based constructs in combination with the res-
ponder TRE-Luc and not, when combined with rTetR-M2.
The dose^response curve for doxycycline showed that the
L-domain derivatives require more doxycycline for maximal
activation than do the Tet-On or M2 constructs, and that the
activation curves span a considerably wider range of concen-
trations (Fig. 3). This feature might be of value if truly dose-
dependent and reproducible inductions are needed. It might,
on the other hand, be problematic to reach such high doxycy-
cline levels in transgenic animals. A levelling o¡ of the dose^
response curve can also be detected comparing the M2 with
the corresponding L-domain variant (M2-11L). As the M2
protein is more sensitive to doxycycline than Tet-On, M2-
11L also shows an earlier maximum activity than Tet-17L.
The observation that a modi¢cation of the activation do-
main a¡ects the ligand-binding properties of the transactiva-
tor seems surprising and cannot be explained by the data
available. It may be speculated that the L-multimer interacts
with the doxycycline-binding domain, possibly leading to a
mutual masking of doxycycline-binding site and DNA-bind-
ing domain. A reduced DNA-binding activity and hence re-
duced background would result if no doxycycline was present.
Addition of relatively large amounts of doxycycline would
saturate the doxycycline-binding domain, and thus liberate
the DNA-binding domain.
The evident reduction of background activity seen with the
L-domain activators could add to the existing tools of Tet-
dependent inducible transactivation systems. The bene¢ts of
the L-domains are most obvious in combination with rtTA
constructs. M2/L domains perform better than M2 alone
combined with the plant virus-derived responders. This is of
importance because the advantage of strongly reduced basal
activities is supported with L-domain-containing transactiva-
tors. This is an advantage that contributes to experiments
dealing, for example, with the expression of suicide genes, as
described by Leuchtenberger et al. [20].
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